Drug Discovery and Collaboration Agreement Announced

Cyclenium Pharma Inc, an emerging pharmaceutical company specialising in the discovery and development of novel drug candidates based on proprietary macrocyclic chemistry and Fundación MEDINA (Fundación Centro de Excelencia en Investigación de Medicamentos Innovadores en Andalucía), a non-profit research organisation established through a private-public partnership between the Government of Andalucía (Spain), the University of Granada and Merck Sharp and Dohme de España SA, have announced the signing of a drug discovery and collaboration agreement. The collaboration will utilise Cyclenium’s proprietary QUEST Library™ of next generation macrocyclic molecules and associated hit-to-clinical candidate optimisation capabilities in concert with the extensive expertise and experience of Fundación MEDINA in infective disease research. The objective of the collaboration is to discover new anti-infective drug candidates effective against a number of clinically important bacterial and fungal pathogens. For Cyclenium, this is the fourth discovery collaboration established over the past year.

“We are extremely excited about entering into this unique drug discovery collaboration with the Fundación MEDINA in one of our therapeutic focus areas,” stated Helmut Thomas, PhD, President & Chief Executive Officer of Cyclenium. “The combination of their superb team and world class expertise in anti-infective research with our CMRT™ Technology and proven development success in the macrocycle arena offers an excellent opportunity for discovering desperately needed novel pharmaceutical agents against high priority, treatment resistant, bacterial and fungal organisms.”

”This relationship represents a strategic collaboration to identify novel drugs in the area of infectious diseases from the exploitation of Cyclenium’s unique library complementing the chemical diversity of our natural product libraries,” said Olga Genilloud, PhD, Scientific Director, Fundación MEDINA. “MEDINA provides the expertise and tools to maximise the probability of success in the collaboration with Cyclenium and the discovery of promising compounds for the treatment of serious multidrug resistant infections.”